此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

评估缓慢增加 KarXT 剂量的安全性和有效性以及食物对精神分裂症患者的影响的研究

2026年6月18日 更新者：Karuna Therapeutics, Inc., a Bristol Myers Squibb company

一项 3b 期、开放标签、多中心、两期、缓慢滴定和食物效应研究，旨在评估 KarXT 对 DSM-5 精神分裂症患者的安全性和有效性

本研究的目的是评估成年精神分裂症患者缓慢增加 KarXT 剂量和食物效应的安全性和有效性。

研究概览

地位

完全的

条件

干预/治疗

研究类型

介入性

注册 (实际的)

173

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 美国
    • California
      • Los Alamitos、California、美国、90720-3118
        • Local Institution - 0002
      • Riverside、California、美国、92506-3257
        • Local Institution - 0004
    • Florida
      • Hollywood、Florida、美国、33024
        • Local Institution - 0006
    • Georgia
      • Atlanta、Georgia、美国、30331
        • Local Institution - 0005
      • Decatur、Georgia、美国、30030
        • Local Institution - 0003
    • New Jersey
      • Marlton、New Jersey、美国、08053-3449
        • Local Institution - 0001

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

纳入标准：

  • 根据 DSM-5（美国精神病学协会 2013 年）标准进行综合精神病学评估，初步诊断为精神分裂症，并经精神分裂症和精神障碍研究小型国际神经精神访谈 (MINI) 7.0.2 版确认。
  • 筛选时和基线时的阳性和阴性症状量表 (PANSS) 总分 ≤ 80。
  • 筛查和基线时的临床总体印象严重性 (CGI-S) 评分 ≤ 4。
  • 愿意并且能够在基线访视之前停止所有抗精神病药物。

排除标准：

  • 有临床意义的心血管、肺、肾、血液、胃肠道 (GI)、内分泌、免疫、皮肤病、神经或肿瘤疾病的病史或存在，或研究者认为会危及参与者安全的任何其他病症或研究结果的有效性。
  • 筛选前 12 个月内患有除精神分裂症以外的任何原发性 DSM-5 疾病。
  • 对精神分裂症药物的治疗耐药史。
  • 对 KarXT 过敏/超敏反应史。
  • 其他协议定义的包含/排除标准适用。

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：非随机化
  • 介入模型：单组作业
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
实验性的：KarXT 空腹和随餐服用
药品：卡尔XT
指定日期的指定剂量
其他名称：
  • BMS-986510

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Number of Participants With TEAEs From First Dose to End of Study Follow up.
大体时间：From first dose to end of study follow up (63 days)

Number of participants with Treatment Emergent Adverse Events (TEAEs) from first dose to end of study follow up.

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.
From first dose to end of study follow up (63 days)
Number of Participants With TEAEs at the End of Period 1 and Period 2.
大体时间：Period 1 (From first dose to day 28) Period 2 (day 29 to day 56)

Number of participants with TEAEs at the end of period 1 and period 2.

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.
Period 1 (From first dose to day 28) Period 2 (day 29 to day 56)
Number of Participants With Serious TEAEs at the End of Period 1 and Period 2.
大体时间：Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)

Number of participants with TEAEs at the end of period 1 and period 2.

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)
Number of Participants With TEAEs Leading to Treatment Discontinuation.
大体时间：Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)
Number of participants with TEAEs leading to treatment discontinuation.
Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)
Number of Participants With Pro-cholinergic and Anticholinergic TEAEs.
大体时间：Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)
The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.
Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)

次要结果测量

结果测量
措施说明
大体时间
Change From Baseline in PANSS Total Score, Positive Score and Negative Score
大体时间：From first dose to end of treatment (56 days)
The Positive and Negative Syndrome Scale (PANSS) assesses schizophrenia symptom severity using 30 items: 7 positive, 7 negative, and 16 general psychopathology scales. Each item is rated from 1 (absent) to 7 (extreme). Positive symptoms represent excesses or distortions of normal function (e.g., hallucinations, delusions), while negative symptoms reflect diminished function. The PANSS positive and negative scores each sum their respective 7 items, ranging from 7 to 49, with higher scores indicating greater severity. The PANSS Total Score sums all 30 items, ranging from 30 to 210, with higher scores reflecting worse overall symptom severity.
From first dose to end of treatment (56 days)
Change From Baseline in Marder Factor Score.
大体时间：From first dose to end of treatment (56 days)
PANSS Marder factor score is the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom scale, with a total score ranging from 7 to 49. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Baseline is defined as the PANSS score at screening.
From first dose to end of treatment (56 days)
Change From Baseline in CGI Severity Score
大体时间：From first dose to end of treatment (56 days)
Completed independently by a clinician, the CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients, by asking the clinical 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness.
From first dose to end of treatment (56 days)
Number of Participants With Spontaneously Reported AESIs
大体时间：From first dose to end of study follow up (63 days)
The AEs of special interest (AESIs) will be monitored and include symptomatic orthostasis, syncope(a transient loss of consciousness or fainting),and liver function test elevations as defined below. For SAE reporting requirements for events of liver injury.
From first dose to end of study follow up (63 days)
Number of Participants With Clinically Significant Changes in Vital Signs
大体时间：From first dose to end of study follow up (63 days)
Number of participants with clinically significant changes in vital signs
From first dose to end of study follow up (63 days)
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
大体时间：From first dose to end of study follow up (63 days)
Number of participants with clinically significant changes in clinical laboratory assessments
From first dose to end of study follow up (63 days)
Number of Participants With Clinically Significant Changes in 12-lead ECGs
大体时间：From first dose to end of study follow up (63 days)
Number of participants with clinically significant changes in 12-lead ECGs
From first dose to end of study follow up (63 days)
Number of Participants Who Exhibited Suicidal Behavior as Assessed by C-SSRS
大体时间：From first dose to end of study follow up (63 days)
Number of participants who exhibited suicidal behavior as assessed by C-SSRS
From first dose to end of study follow up (63 days)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

调查人员

  • 研究主任：Bristol-Myers Squibb、Bristol-Myers Squibb

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年10月28日

初级完成 (实际的)

2025年3月13日

研究完成 (实际的)

2025年3月13日

研究注册日期

首次提交

2024年8月8日

首先提交符合 QC 标准的

2024年8月22日

首次发布 (实际的)

2024年8月27日

研究记录更新

最后更新发布 (实际的)

2026年6月22日

上次提交的符合 QC 标准的更新

2026年6月18日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • CN012-0048

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

是的

IPD 计划说明

BMS 将根据合格研究人员的要求并遵守某些标准，提供对个人匿名参与者数据的访问。

有关百时美施贵宝数据共享政策和流程的更多信息，请访问：

https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

IPD 共享时间框架

请参阅计划说明

IPD 共享访问标准

请参阅计划说明

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅